• Digital therapeutics: An effective, non-pharmacologic way to improve BP control

    The digital HERB system proved successful in early-stage hypertension patients, which could lower their blood pressure and adopt positive lifestyle interventions.

  • Older patients profit from intensified blood pressure treatment

    The STEP trial revealed that lowering systolic blood pressure below 130 mmHg in +60 year-old patients led to a 26% reduction of adverse cardiovascular events.

  • The Transparent Senses and their implications for depersonalisation

    Dr. Anna Ciaunica gave an insight into her work at the INSIGHT 2021 Conference and explained how the COVID-19 crisis-induced lack of tactile experience favours a depersonalitation disorder.

  • Psychedelic therapy: How it works and where danger hides

    Psychedelic therapy and psychotherapy - differences and similarities and potential problems for therapists. Prof. Matthew Johnson (Johns Hopkins University) shared his work at the INSIGHT 2021 Conference.

  • Are psychedelics a solution to the mental health crisis?

    Psychedelics could represent a new treatment approach in psychiatry. But can they combat the global health crisis? At the INSIGHT 2021 Conference, Prof. Dr. Gerhard Gründer takes a critical look on the issue.

  • Can breathwork alter consciousness?

    For neuroscientist Dr. Martha Havenith, psychedelics are not the only way to explore altered states of consciousness. She works with voluntary hyperventilation (Breathwork) to achieve different perceptions.

  • Immediate angiogram after cardiac arrest does not reduce mortality

    Assigning all survivors of an out-of-hospital cardiac arrest (OHCA) to an early coronary angiogram turned out to have no positive influence on the 30-day all-cause mortality.

  • Therapeutic heparin dosage benefits COVID-19 patients

    Thromboprophylaxis with a heparin therapeutic dose greatly reduced major thromboembolic events in COVID-19 hospitalisations compared with standard therapy.

  • Psychedelics: Paradigm shift for mental health?

    In parts of public discourse and scientific literature, psychedelic therapies are claimed to transform and revolutionise psychiatry and mental healthcare. Can psychedelics live up to this claim?

  • Rivaroxaban improves clinical outcomes in discharged COVID-19 patients

    The MICHELLE trial found rivaroxaban thrombo-prophylaxis beneficial for COVID-19 patients. Some individuals had a 67% risk reduction in clinical outcome composites.

  • Dr. Haegy, fighting for conviction single-handedly

    Amidst anti-vaccine passport demonstrators, a masked Dr. Haegy stands alone, with a handmade sign reminding us of some figures: 2,000 intensive care patients, of which 85% were not vaccinated.

  • The lasting battle of COVID-19 long-haulers

    Months after infection with SARS-CoV-2, some people are still battling fatigue. In a study, severe fatigue was negatively correlated with disease severity up to 10 months after initial infection.

  • Livestock farming affects the airway microbiome of COPD patients

    Intensive livestock has been associated with health risks. Residential exposure to its emitted endotoxin was linked to increased species richness in COPD.

  • Polypill including aspirin most successful for CVD event prevention

    A meta-analysis of three large primary prevention trials showed fixed-dose combination treatments help prevent CV death, MI, stroke, or revascularisation.

  • Finerenone benefits diabetics with chronic kidney disease

    The FIGARO-DKD trial investigated mineralocorticoid receptor antagonist treatment effects on cardiovascular outcomes in patients with mild-to-moderate kidney disease and T2D.

  • How respiratory muscle training can help in COVID-19 recovery

    IMT consists of breathing exercises. It is a home-based rehabilitation tool that contributes significantly to COVID-19 recovery with only 3 sessions per week.

  • Salt substitute: An effective way to lower salt intake and blood pressure

    The DECIDE-Salt trial assessed dietary sodium-reduction strategies over 2 years in residential care patients, targeting significant reductions in systolic blood pressure.

  • VOYAGER PAD analysis shows similar treatment benefit in diabetic patients

    The study showed that diabetic patients with symptomatic PAD and recent peripheral artery revascularisation share benefits from low-dose rivaroxaban with non-diabetics.

  • ‘Quadpill’ more successful in reducing BP than monotherapy

    Starting with a quadruple combination of hypertensive agents in tiny doses showed to be more effective than standard monotherapy in blood pressure (BP) control.

  • Dapagliflozin reduces incidence of sudden death in HFrEF patients

    A novel analysis of DAPA-HF investigated the efficacy of dapagliflozin on ventricular arrhythmia, resuscitated cardiac arrest, and sudden death showing a very reduced likelihood for composite outcome by 21%.

  • 39 |
  • 40 |
  • 41 |
  • 42 |
  • 43 |
  • 44 |
  • 45 |
  • 46 |
  • 47 |
  • 48 |
  • 49 |